Business Description
Theseus Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
Description
Theseus Pharmaceuticals Inc is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. The company's development programs are designed to address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 55.26 | |||||
| Equity-to-Asset | 0.96 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.06 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -50.1 | |||||
| 3-Year EPS without NRI Growth Rate | -29.5 | |||||
| 3-Year FCF Growth Rate | -29.1 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 6.03 | |||||
| 9-Day RSI | 13.83 | |||||
| 14-Day RSI | 22.74 | |||||
| 6-1 Month Momentum % | -63.74 | |||||
| 12-1 Month Momentum % | -44.48 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 27.83 | |||||
| Quick Ratio | 27.83 | |||||
| Cash Ratio | 27.1 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -48.1 | |||||
| Shareholder Yield % | 0.13 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -25.49 | |||||
| ROA % | -24.27 | |||||
| ROIC % | -323.9 | |||||
| ROC (Joel Greenblatt) % | -1392.8 | |||||
| ROCE % | -28.64 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.48 | |||||
| Price-to-Tangible-Book | 0.48 | |||||
| EV-to-EBIT | 1.32 | |||||
| EV-to-EBITDA | 1.32 | |||||
| EV-to-FCF | 1.9 | |||||
| Price-to-Net-Current-Asset-Value | 0.55 | |||||
| Price-to-Net-Cash | 0.57 | |||||
| Earnings Yield (Greenblatt) % | 75.76 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:THRX
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Theseus Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.41 | ||
| Beta | 0 | ||
| Volatility % | 211.3 | ||
| 14-Day RSI | 22.74 | ||
| 14-Day ATR ($) | 0.139979 | ||
| 20-Day SMA ($) | 2.861 | ||
| 12-1 Month Momentum % | -44.48 | ||
| 52-Week Range ($) | 2.56 - 14.7672 | ||
| Shares Outstanding (Mil) | 43.6 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Theseus Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Theseus Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Theseus Pharmaceuticals Inc Frequently Asked Questions
What is Theseus Pharmaceuticals Inc(THRX)'s stock price today?
The current price of THRX is $2.57. The 52 week high of THRX is $14.77 and 52 week low is $2.56.
When is next earnings date of Theseus Pharmaceuticals Inc(THRX)?
The next earnings date of Theseus Pharmaceuticals Inc(THRX) is 2023-11-03 Est..
Does Theseus Pharmaceuticals Inc(THRX) pay dividends? If so, how much?
Theseus Pharmaceuticals Inc(THRX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers